$50,000 of SANOFI US SERVICES INC. lobbying was just disclosed, from Q3 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21). Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2026 National Defense Authorization Act, S.2296/H.R.3838), insulin price cap, VICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues."
You can find more data on corporate lobbying on Quiver Quantitative.
SNY Congressional Stock Trading
Members of Congress have traded $SNY stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $SNY stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 2 purchases worth up to $30,000 on 08/04, 06/17 and 1 sale worth up to $15,000 on 07/22.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
SNY Hedge Fund Activity
We have seen 329 institutional investors add shares of SNY stock to their portfolio, and 356 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 5,511,133 shares (-49.9%) from their portfolio in Q2 2025, for an estimated $266,242,835
- INVESCO LTD. removed 2,671,341 shares (-22.5%) from their portfolio in Q2 2025, for an estimated $129,052,483
- RAYMOND JAMES FINANCIAL INC added 2,635,867 shares (+81.3%) to their portfolio in Q2 2025, for an estimated $127,338,734
- DODGE & COX removed 1,474,742 shares (-2.0%) from their portfolio in Q2 2025, for an estimated $71,244,786
- BANK OF NEW YORK MELLON CORP removed 1,452,581 shares (-74.7%) from their portfolio in Q2 2025, for an estimated $70,174,188
- THRIVENT FINANCIAL FOR LUTHERANS removed 1,446,552 shares (-92.3%) from their portfolio in Q2 2025, for an estimated $69,882,927
- FMR LLC removed 1,089,860 shares (-23.2%) from their portfolio in Q2 2025, for an estimated $52,651,136
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SNY Analyst Ratings
Wall Street analysts have issued reports on $SNY in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 09/08/2025
- Deutsche Bank issued a "Buy" rating on 09/02/2025
- JP Morgan issued a "Overweight" rating on 08/08/2025
To track analyst ratings and price targets for SNY, check out Quiver Quantitative's $SNY forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
